BPC-157 Rebound Effects When Stopping: What the Evidence Actually Shows

Does stopping BPC-157 cause a rebound?

A rebound means the treated problem returns worse than before treatment. How BPC-157 works in people remains poorly understood: FDA's July 2026 reviewers said its molecular targets have not been identified and that dose-response relationships for the reported protective effects were not established [2]. If symptoms return after stopping BPC-157, the available studies cannot tell whether they have returned to baseline or become worse than before treatment [1][3].

What the human studies measured

A 2026 systematic review found three eligible studies, 30 patients, all of poor methodological quality, with certainty of evidence rated very low [3]. A retrospective knee-pain review at one Florida clinic reached 16 of 17 patients by phone; 11 of the 12 who received BPC-157 alone reported significant improvement, but there was no control group and most patients were recalling results six months to a year later [1]. In a single-arm interstitial cystitis pilot, 12 women received 10 mg total injected around the bladder wall; 10 reported complete resolution and 2 about 80 percent [6]. A two-person intravenous pilot gave 10 mg on day 1 and 20 mg on day 2, and found no measurable change in tested organ or glucose markers and no reported side effects [7].

How long does BPC-157 stay in the body?

Unknown for the usual routes. FDA found no human pharmacokinetic data for oral, subcutaneous, nasal or skin use [2]. After rectal enemas, BPC-157 was mostly not detectable in blood, and FDA judged it appears not to be absorbed systemically that way [2].

What is known about safety

FDA's adverse-event search through December 4, 2025 found three reports, all involving injectable BPC-157: injection-site redness and swelling for nine days; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred after re-exposure to a BPC-157 plus TB-500 product. FDA said it cannot tell whether BPC-157 caused these [2]. In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short and small [2]. FDA concluded there is insufficient clinical safety information to characterize the safety profile of BPC-157, and found no human studies of it given by mouth, subcutaneous injection, nasal spray or skin [2]. In 28-day intramuscular animal studies, BPC-157 shortened clotting time in rats and prolonged it in dogs, and raised liver enzyme, glucose and triglyceride levels [2].